Acceleron Pharma Inc. (NASDAQ:XLRN) SVP John D. Quisel sold 5,113 shares of the stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $38.42, for a total value of $196,441.46. Following the completion of the sale, the senior vice president now directly owns 57,918 shares of the company’s stock, valued at approximately $2,225,209.56. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Acceleron Pharma Inc. (NASDAQ XLRN) traded up 0.03% on Friday, reaching $39.91. The company’s stock had a trading volume of 528,858 shares. Acceleron Pharma Inc. has a 12 month low of $23.07 and a 12 month high of $41.69. The firm’s market cap is $1.54 billion. The firm has a 50 day moving average of $35.71 and a 200 day moving average of $30.87.
Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.12). Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. The business had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $3.69 million. During the same period in the prior year, the firm posted ($0.59) EPS. The firm’s revenue for the quarter was down 3.1% on a year-over-year basis. Analysts anticipate that Acceleron Pharma Inc. will post ($2.72) earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of the business. Teachers Advisors LLC lifted its position in shares of Acceleron Pharma by 3.0% during the 4th quarter. Teachers Advisors LLC now owns 45,138 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 1,296 shares during the last quarter. Bank of Montreal Can purchased a new position in shares of Acceleron Pharma during the 1st quarter valued at $237,000. Nationwide Fund Advisors lifted its position in shares of Acceleron Pharma by 10.5% during the 1st quarter. Nationwide Fund Advisors now owns 22,737 shares of the biopharmaceutical company’s stock valued at $602,000 after buying an additional 2,168 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Acceleron Pharma by 88.9% during the 1st quarter. Russell Investments Group Ltd. now owns 27,850 shares of the biopharmaceutical company’s stock valued at $737,000 after buying an additional 13,108 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its position in shares of Acceleron Pharma by 106.1% during the 1st quarter. Wells Fargo & Company MN now owns 79,462 shares of the biopharmaceutical company’s stock valued at $2,104,000 after buying an additional 40,910 shares during the last quarter. 88.07% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts have recently commented on XLRN shares. Credit Suisse Group set a $35.00 price objective on Acceleron Pharma and gave the company a “buy” rating in a report on Saturday, August 5th. Oppenheimer Holdings, Inc. reissued a “market perform” rating on shares of Acceleron Pharma in a report on Tuesday, June 13th. Piper Jaffray Companies increased their price objective on Acceleron Pharma from $32.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, June 26th. Cann reissued a “hold” rating on shares of Acceleron Pharma in a report on Tuesday, September 5th. Finally, BidaskClub downgraded Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Acceleron Pharma currently has an average rating of “Buy” and a consensus target price of $42.33.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.